[go: up one dir, main page]

AR069230A1 - Inhibidores de peptido desformilasa - Google Patents

Inhibidores de peptido desformilasa

Info

Publication number
AR069230A1
AR069230A1 ARP080104885A ARP080104885A AR069230A1 AR 069230 A1 AR069230 A1 AR 069230A1 AR P080104885 A ARP080104885 A AR P080104885A AR P080104885 A ARP080104885 A AR P080104885A AR 069230 A1 AR069230 A1 AR 069230A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
groups
group
alkyl
nrarb
Prior art date
Application number
ARP080104885A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40626160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR069230(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR069230A1 publication Critical patent/AR069230A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a derivados de {2-(alquil)-3-[2-(5-fluoro-4-pirimidinil)hidrazino]-3-oxopropil}hidroxiformamida, a composiciones que los contienen y al uso de dichos compuestos en la inhibicion de la actividad péptido desformilasa bacteriana (PDF) y en el tratamiento de infecciones bacterianas. También se refiere a diferentes formas polimorficas. Reivindicacion 1: Un compuesto de acuerdo con la formula (1): en la que R1 se selecciona entre el grupo que consiste en alquilo C2-7 y -(CH2)n-cicloalquilo C3-6; R2 se selecciona entre el grupo que consiste en alquilo C1-3; ciclopropilo; alcoxi C1-3; haloalquilo C1-3; sulfanilo C1-3; heteroarilo de 5 miembros; heterocicloalquilo de 5 miembros; halogeno; hidroximetilo; y -NRaRb; R3 se selecciona entre el grupo que consiste en -NR4R5; halogeno; fenilo, opcionalmente sustituido con uno a tres grupos R6; y heteroarilo, opcionalmente sustituido con uno a tres grupos R6; R4 se selecciona entre el grupo que consiste en H; alquilo C1-6, opcionalmente sustituido con uno o dos grupos R7; alcoxi C1-6; cicloalquilo C3-6, opcionalmente sustituido con uno a tres grupos R6; heterocicloalquilo, opcionalmente sustituido con uno a tres grupos R6; heteroarilo, opcionalmente sustituido con uno a tres grupos R6; y fenilo, opcionalmente sustituido con uno a tres grupos R6; R5 se selecciona entre H; alquilo C1-6, opcionalmente sustituido con uno o dos grupos R7; alcoxi C1-6; cicloalquilo C3-6, opcionalmente sustituido con uno a tres grupos R6; heterocicloalquilo, opcionalmente sustituido con uno a tres grupos R6; heteroarilo, opcionalmente sustituido con uno a tres grupos R6; y fenilo, opcionalmente sustituido con uno a tres grupos R6; o R4 y R5 se unen junto con el átomo de N al que están unidos, formando un grupo heterocicloalquilo opcionalmente sustituido con uno a tres grupos R6; cada R6 se selecciona independientemente entre el grupo que consiste en alquilo C1-6, opcionalmente sustituido con uno a tres grupos R7; hidroxi; alcoxi C1-3; -C(O)NRaRb; -C(O)Rc; -C(O)ORc; heterocicloalquilo; cicloalquilo C3-6 opcionalmente sustituido con un -NRaRb o pirrolidinilo; oxo; ciano; -NRaRb; fenilo; heteroarilo; y halo; cada R7 se selecciona independientemente entre el grupo que consiste en hidroxi; alcoxi C1-3; halogeno; fenilo; ciano; -NRaRb; -C(O)NRaRb; -C(O)Rc; cicloalquilo C3-6, opcionalmente sustituido con un hidroxi, heterocicloalquilo o un grupo -NRaRb; heterocicloalquilo; y heteroarilo opcionalmente sustituido con un metilo, NRaRb o hidroxi; cada Ra se selecciona independientemente entre el grupo que consiste en H y alquilo C1-3 opcionalmente sustituido con un hidroxi, metoxi o dimetilamina; cada Rb se selecciona independientemente entre el grupo que consiste en H y alquilo C1-3; cada Rc se selecciona independientemente entre el grupo que consiste en alquilo C1-3 opcionalmente sustituido con un metoxi; fenilo; heterocicloalquilo; y heteroarilo; y n es un numero entero de 0 a 2; o una sal del mismo.
ARP080104885A 2007-11-09 2008-11-07 Inhibidores de peptido desformilasa AR069230A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98663107P 2007-11-09 2007-11-09

Publications (1)

Publication Number Publication Date
AR069230A1 true AR069230A1 (es) 2010-01-06

Family

ID=40626160

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104885A AR069230A1 (es) 2007-11-09 2008-11-07 Inhibidores de peptido desformilasa

Country Status (22)

Country Link
US (2) US20130045962A1 (es)
EP (1) EP2217226B1 (es)
JP (1) JP5728229B2 (es)
KR (2) KR20100110774A (es)
CN (1) CN101917981B (es)
AR (1) AR069230A1 (es)
AU (1) AU2008323998B2 (es)
CA (1) CA2705246A1 (es)
CL (1) CL2008003326A1 (es)
CO (1) CO6270305A2 (es)
CR (1) CR11483A (es)
EA (1) EA018953B1 (es)
ES (1) ES2549879T3 (es)
MA (1) MA31873B1 (es)
MX (1) MX2010005188A (es)
NZ (1) NZ585221A (es)
PE (1) PE20090984A1 (es)
PH (1) PH12013501288A1 (es)
TW (2) TW200934763A (es)
UA (1) UA108596C2 (es)
UY (1) UY31463A1 (es)
WO (1) WO2009061879A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27813A1 (es) 2002-05-31 2003-12-31 Smithkline Beecham Corp Inhibidores de la peptido-desformilasa
MX2013002530A (es) 2010-09-13 2013-03-22 Otsuka Pharma Co Ltd Compuestos heterociclicos para tratar o prevenir trastornos causados por neurotransmision reducida de serotonina, norepinefrina o dopamina.
AR085698A1 (es) * 2011-03-09 2013-10-23 Glaxosmithkline Llc Inhibidores de la peptido desformilasa
US20140194383A1 (en) 2011-04-07 2014-07-10 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
CA2857694A1 (en) * 2011-12-02 2013-06-06 Glaxosmithkline Intellectual Property (No.2) Limited Peptide deformylase inhibitors
US9309273B2 (en) 2011-12-11 2016-04-12 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN102875482A (zh) * 2012-10-15 2013-01-16 盛世泰科生物医药技术(苏州)有限公司 一种十氢喹喔啉的合成方法
WO2014141181A1 (en) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property No 2 Limited Process for preparing peptide deformylase inhibitors
JP2017507915A (ja) 2014-01-10 2017-03-23 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited ヒドロキシホルムアミド誘導体およびそれらの使用
WO2015116242A1 (en) * 2014-02-03 2015-08-06 Brandeis University Supramolecular hydrogel of fmlf-based molecules and use thereof
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
CN104725323A (zh) * 2014-10-16 2015-06-24 江苏华益科技有限公司 一种2-甲氧基-4-肼基-5-氟嘧啶的合成工艺
CN107207521A (zh) 2014-11-19 2017-09-26 葛兰素史密斯克莱知识产权(第2 号)有限公司 作为沉默调节蛋白调节剂的取代的桥连脲类似物
WO2017006295A1 (en) 2015-07-08 2017-01-12 Glaxosmithkline Intellectual Property (No.2) Limited Hydroxy formamide derivatives and their use
KR20180052755A (ko) 2015-09-18 2018-05-18 브이피에스-3, 인크. 항진균 화합물 및 이의 제조방법
ES2921257T3 (es) 2016-06-20 2022-08-22 Daegu Gyeongbuk Medical Innovation Found Nuevo derivado de imidazopiridina, procedimiento para prepararlo y composición farmacéutica que contiene el mismo como ingrediente activo para prevenir o tratar el cáncer
CN113683596B (zh) * 2021-08-17 2023-02-10 上海应用技术大学 一种嘧啶类端锚聚合酶2抑制剂及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
US6028110A (en) * 1994-05-28 2000-02-22 British Biotech Pharmaceuticals Ltd. Succinyl hydroxamic acid, N-formyl-N-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
GB9903119D0 (en) 1999-02-11 1999-04-07 Merck Sharp & Dohme Therapeutic agents
US6852752B2 (en) * 1999-12-17 2005-02-08 Vicuron Pharmaceuticals Inc. Urea compounds, compositions and methods of use and preparation
DE10040783A1 (de) 2000-08-21 2002-03-07 Merck Patent Gmbh AZA-Aminosäurederivate (Faktor X¶a¶-Inhibitoren 15)
UY27192A1 (es) * 2001-03-01 2002-09-30 Smithkline Beecham Corp Inhibidores de peptido-deformilasa
UY27813A1 (es) * 2002-05-31 2003-12-31 Smithkline Beecham Corp Inhibidores de la peptido-desformilasa
GB0228365D0 (en) 2002-12-05 2003-01-08 British Biotech Pharm Antibacterial agents
GB0229673D0 (en) 2002-12-19 2003-01-29 British Biotech Pharm Antibacterial agents
US7332485B2 (en) * 2003-07-08 2008-02-19 Smithkline Beecham Corp Peptide deformylase inhibitors
WO2005026146A1 (en) 2003-09-12 2005-03-24 Warner-Lambert Company Llc Azetidinyl quinolones as antibacterial agents
CA2546339A1 (en) 2003-11-18 2005-06-02 Warner-Lambert Company Llc Antibacterial aminoquinazolidinedione derivatives
US7102001B2 (en) 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
HRP20090471T1 (hr) 2004-05-12 2009-10-31 Pfizer Products Inc. Derivati prolina i njihova upotreba kao inhibitori dipeptidil-peptidaze iv
EP1827449A4 (en) 2004-11-17 2008-01-23 Smithkline Beecham Corp USE OF NOVEL ANTIBACTERIAL COMPOUNDS
GT200600196A (es) 2005-05-23 2007-01-15 Compuestos n-formil de hidroxilamina
US20070197512A1 (en) * 2006-01-27 2007-08-23 Japan Tobacco Inc. Carboxylic Acid Compounds and Use Thereof

Also Published As

Publication number Publication date
JP2011503092A (ja) 2011-01-27
US7893056B2 (en) 2011-02-22
MX2010005188A (es) 2010-05-27
KR20160040321A (ko) 2016-04-12
NZ585221A (en) 2012-05-25
ES2549879T3 (es) 2015-11-02
CO6270305A2 (es) 2011-04-20
EA201070592A1 (ru) 2010-12-30
EP2217226B1 (en) 2015-07-22
CL2008003326A1 (es) 2010-03-05
AU2008323998A1 (en) 2009-05-14
AU2008323998B2 (en) 2013-01-10
CN101917981A (zh) 2010-12-15
KR20100110774A (ko) 2010-10-13
TW200934763A (en) 2009-08-16
CN101917981B (zh) 2012-11-14
EP2217226A4 (en) 2012-03-21
MA31873B1 (fr) 2010-11-01
UA108596C2 (xx) 2015-05-25
CA2705246A1 (en) 2009-05-14
EP2217226A1 (en) 2010-08-18
UY31463A1 (es) 2009-05-29
JP5728229B2 (ja) 2015-06-03
WO2009061879A1 (en) 2009-05-14
US20130045962A1 (en) 2013-02-21
HK1144070A1 (zh) 2011-01-28
CR11483A (es) 2010-09-21
US20090306066A1 (en) 2009-12-10
EA018953B1 (ru) 2013-12-30
TW201441218A (zh) 2014-11-01
PE20090984A1 (es) 2009-08-07
PH12013501288A1 (en) 2015-02-09

Similar Documents

Publication Publication Date Title
AR069230A1 (es) Inhibidores de peptido desformilasa
AR074790A1 (es) Derivados de isooxazol sustituidos, composiciones farmaceuticas y para el control de parasitos que los comprenden y su uso en metodos para controlar parasitos en y sobre animales de sangre caliente.
ECSP18072109A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de jak campo de la invención
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR081998A1 (es) Compuestos de isoxazolinas, composicion para el control de parasitos en base al compuesto, metodo de control de parasitos y uso del compuesto para tal fin
AR085354A1 (es) Derivados de isoxazol para control de pestes invertebrados
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
RU2016135922A (ru) Терапевтические соединения и композиции
AR085657A1 (es) Compuestos de isoxazol
AR044152A1 (es) Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
AR078888A1 (es) Derivados heterociclicos nitrogenados de bencimidazol-imidazol utiles para tratar infecciones por hvc y composiciones farmaceuticas que los comprenden.
JP2008505194A5 (es)
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
AR063151A1 (es) Inhibidores de metaloproteasas de matriz
MX2022002362A (es) Derivado de 2-aminoquinazolinona.
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
AR067008A1 (es) Derivados 3- amino-6-(1- amino - etil)-tetrahidropirano
AR076401A1 (es) Bisaril alquinilamidas como moduladores alostericos negativos del receptor metabotropico de glutamato 5 (mglur5)
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR049418A1 (es) Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
AR083832A1 (es) DERIVADOS DE TETRAHIDROPIRIDO[3,2-F][1,4]OXAZEPIN-8-AMINA PARA EL TRATAMIENTO DE ENFERMEDADES Ab-RELACIONADAS
AR077819A1 (es) Compuestos heterociclicos antagonistas de esfingosina -1-fosfato (sip)
PE20211456A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado

Legal Events

Date Code Title Description
FB Suspension of granting procedure